Why the UK must put medicines at the forefront of a new EU relationship Whisky, frozen prawns, olives and sausages have all featured prominently in the UK’s early trade negotiations with partners from India to the EU and, most recently, China​1–4​. However, in the search…

Here, #MarkSamuels argues why the UK's priorities need to change in terms of medicines regulation, which will ultimately determine whether future patients will benefit from affordable medicines supply

#medicinesregulation #ukhealthcare #supplychain

Join us at the HMA/EMA Annual Data Forum 2025 to shape the future of data-driven medicines regulation in the EU!

📅 9 Dec 2025
📍 Amsterdam & Virtual

Shape the next chapter. Register now: www.ema.europa.eu/en/events/em...

#MedicinesRegulation #DataScience

‪👋Hi everyone! We are an interdisciplinary group of researchers from @unibirmingham.bsky.social working on the the legal, ethical, social, and other challenges relating to the therapeutic use of psychedelics (e.g. psilocybin & MDMA). #Psychedelics #PsychedelicResearch #MedicinesRegulation

Delighted to have welcomed participants to Birmingham last week for our roundtable on Psychedelics & Regulatory Decision-making. V interesting & fruitful discussion with a range of perspectives. #Psychedelics #PsychedelicExperience #PsychedelicResearch #PsychedelicMedicine #MedicinesRegulation

The Windsor Framework and Its Implications for Unlicensed Medicines ('Specials') In light of the uncertainty surrounding whether the Windsor Framework applies to specials, we contacted the Medicines and Healthcare products Regulatory Agency (MHRA) to seek clarification. The query aimed to determine whether unlicensed medicines would need to adhere to the 'UK Only' labelling requirements and where relevant guidance could be found.

Discover how the Windsor Framework affects the regulation and labelling of medicinal products across the UK. Read MHRA’s clarifications for unlicensed medicines on the CTA website. #CTAUK #CannabisTrades #PharmaStandards #HealthcareUpdate #MedicinesRegulation

Manufacturer offers NHS £23m in response to investigation into misleading claims about rival treatment Drugs manufacturer Vifor Pharma has offered to pay £23m to the NHS in response to an investigation by the Competition and Markets Authority (CMA) into whether the company had broken competition law by...

Manufacturer offers NHS £23m in response to investigation into misleading claims about rival treatment
#medicinesregulation #NHS #CMA

pharmaceutical-journal.com/article/news...